The EPS projection of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) for quarter ended 2016-09-30 is $-0.2. A week before, the EPS forecast was $-0.2 against target of $-0.2, a month earlier. This estimate stood at $-0.2 60 days earlier versus forecast of $-0.2 90 days earlier, confirming a deviation of 0%.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 2, 0 and 2, respectively.
The downgrade of EPS estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the preceding 120, 60, 30 and 90 days were 1, 2, 0 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was $-0.2. This projection was computed after accounting 7 calls. As reported on 2016-05-05 the EPS was $-0.31. The change was $-0.08, demonstrating a percentage deviation of -34.78%. The projections confirmed a standard deviation of 0.01.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stands at $5.163 and the median estimate at $4.974. Almost 4 analysts announced their estimates.
The highest estimate is $6.484 while the lowest target is $4.22 showing standard deviation of 0.986%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of -4.211%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stated that the change in forecast was -16.98%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...